Literature DB >> 18494831

Invasive T1 bladder cancer: indications and rationale for radical cystectomy.

John P Stein1, David F Penson.   

Abstract

Invasive T1 bladder cancers are potentially lethal tumours with varying degrees of aggressiveness and progression. The management of invasive tumours can be very difficult and includes bladder-sparing with transurethral resection and intravesical therapy, or a more aggressive approach with radical cystectomy. Certain clinical and pathological factors might provide some risk stratification for invasive T1 tumours, and might better direct the physician towards an earlier cystectomy for some patients. This review provides a rationale for a radical cystectomy in patients with high-risk, invasive T1 bladder cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18494831     DOI: 10.1111/j.1464-410X.2008.07743.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

1.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

2.  Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Authors:  Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

Review 3.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

4.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.

Authors:  Jacob T Ark; Kirk A Keegan; Daniel A Barocas; Todd M Morgan; Matthew J Resnick; Chaochen You; Michael S Cookson; David F Penson; Rodney Davis; Peter E Clark; Joseph A Smith; Sam S Chang
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

5.  Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

Authors:  Richard E Hautmann; Bjoern G Volkmer; Kilian Gust
Journal:  World J Urol       Date:  2009-03-25       Impact factor: 4.226

6.  Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder.

Authors:  Vincenzo DE Marco; Maria Angela Cerruto; Carolina D'Elia; Matteo Brunelli; Oscar Otte; Anila Minja; Claudio Luchini; Giovanni Novella; Stefano Cavalleri; Guido Martignoni; Walter Artibani
Journal:  Mol Clin Oncol       Date:  2014-05-08

7.  The natural history of secondary muscle-invasive bladder cancer.

Authors:  Guy Hidas; Dov Pode; Amos Shapiro; Ran Katz; Liat Appelbaum; Galina Pizov; Kevin C Zorn; Ezekiel H Landau; Mordechai Duvdevani; Ofer N Gofrit
Journal:  BMC Urol       Date:  2013-05-08       Impact factor: 2.264

8.  Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer.

Authors:  Gang Li; Hualin Song; Jiaxin Wang; Yali Bao; Yuanjie Niu
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

9.  Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.

Authors:  Jamie B Oughton; Heather Poad; Maureen Twiddy; Michelle Collinson; Victoria Hiley; Kathryn Gordon; Mark Johnson; Sunjay Jain; Aidan P Noon; Rohit Chahal; Matt Simms; Mohantha Dooldeniya; Phillip Koenig; Louise Goodwin; Julia M Brown; James W F Catto
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

10.  Genomic characterization of high-risk non-muscle invasive bladder cancer.

Authors:  Joshua J Meeks; Benedito A Carneiro; Sachin G Pai; Daniel T Oberlin; Alfred Rademaker; Kyle Fedorchak; Sohail Balasubramanian; Julia Elvin; Nike Beaubier; Francis J Giles
Journal:  Oncotarget       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.